Die Veranstalter des BOOM Summit bezeichnen die Premiere als gelungen. Auf der Basler Gesundheitskonferenz tauschten 500 Fachleute am 10. und 11. April ihr Wissen aus und informierten sich über innovative digitale Technologien. Den Wettbewerb Innovation Showcase gewann aiEndoscopic aus Zürich. Die erstmals in Basel durchgeführte Gesundheitskonferenz BOOM Summit hat ihre Feuertaufe bestanden. Dies ist […] Erster BOOM Summit war erfolgreich
Die Pregnolia AG ist eine der zehn Finalistinnen zur Präsentation ihrer Diagnostikmethoden am Women’s Health Innovation Summit Europe. Das Fachtreffen findet am 16. und 17. April in Basel statt. Pregnolia ist laut einer Medienmitteilung auf LinkedIn eine der zehn Finalistinnen, die ausgewählt wurde, um auf dem Women’s Health Innovation Summit Europe ihre Methoden zu präsentieren. […] Pregnolia steht bei Women’s Health Innovation Summit Europe im Finale
Fotokite hat in seiner jüngsten Serie-B-Finanzierungsrunde 10 Millionen Franken erlöst. Mit diesen Mitteln strebt die Firma die weitere Internationalisierung der Märkte ihres Systems zur Luftaufklärung für Notfallteams an. Ausserdem sollen Forschung und Entwicklung gestärkt werden. Das Zürcher Unternehmen Fotokite hat in einer Serie-B-Finanzierungsrunde 10 Millionen Franken eingenommen. Sie wurde von der Hamburger Beteiligungsgesellschaft Carbyne Equity […] Fotokite sichert sich 10 Millionen Franken Kapital
WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has commenced an underwritten public offering of $125 million of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase shares of voting common stock. All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan. TScan intends to grant the underwriters a 30-day option to purchase additional shares of its voting common stock in an amount equal to 15% of the securities offered in the public offering. The offering is subject to market, regulatory and other…
REYKJAVIK, ICELAND & PARSIPPANY, NJ — Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the United States. Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference. TEZSPIRE is a registered trademark of Amgen Inc. and AstraZeneca. https://www.azpicentral.com/pi.html?product=tezspire
Researchers from Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, have discovered a new class of Pol? inhibitors featuring central scaffolding rings, designed using Chemistry42, the Company’s proprietary generative AI platform. According to the findings, the AI-enabled molecules exhibited significant enzymatic and cellular potency and promising druglike properties, pointing to a novel strategy for targeting Pol?. The research was published in Bioorganic & Medicinal Chemistry, an Elsevier peer-reviewed journal focusing on molecular chemistry and biology. Aiming for a novel and potent Pol? inhibitor with new cores, the Insilico R&D team implemented both ligand-based drug design (LBDD) and structure-based drug design (SBDD) strategies. Based on novel central scaffold rings innovated with the help of Chemistry42, a promising lead compound was identified, and further optimization for improved potency and other druglike properties yielded 3-hydroxymethyl-azetidine derivatives as a novel…
Forscher der Analysis Group , einem weltweit führenden Unternehmen im Bereich Gesundheitsökonomie und Ergebnisforschung (HEOR), haben die erste groß angelegte Studie mitverfasst, die Rassenunterschiede bei der Behandlung, dem Überleben und dem Zugang zur Gesundheitsversorgung aufgedeckt hat Patienten mit metastasiertem kastrationssensitivem Prostatakrebs (mCSPC) seit der Zulassung der ersten neuartigen Hormontherapie im Jahr 2018. Die in der Fachzeitschrift Prostate Cancer and Prostatic Diseases veröffentlichte Studie ergab, dass schwarze Patienten deutlich seltener neuartige Behandlungen für – und erhielten hatten ein höheres Risiko, an mCSPC zu sterben als weiße Patienten. Gesundheitsergebnissen nach Rasse und sozioökonomischem Status zu verstehen. Gemäß den medizinischen Richtlinien zur Behandlung von mCSPC definierte die Studie TI als Patienten, die Docetaxel erhielten; neuartige Hormontherapie (Abirateron, Apalutamid oder Enzalutamid); oder beides, zusätzlich zur Androgendeprivationstherapie (ADT). Die Ergebnisse zeigen Folgendes: Bei schwarzen Patienten war die Wahrscheinlichkeit, TI zu erhalten, weitaus geringer als bei…
NULIBRY is the first and only treatment in Great Britain for patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years The Medicines and Healthcare products Regulatory Agency’s (MHRA) decision is based on efficacy and safety data collected to date. MoCD Type A is known to impact fewer than 150 patients globally with a median survival age of four years. NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy that was approved by the U.S. Food and Drug Administration (FDA) in 2021 to reduce the risk of mortality in patients with MoCD Type A. Following this decision by the MHRA, NULIBRY is the first and only approved therapy in GB for MoCD Type A. https://sentynl.com/news/sentynl-therapeutics-receives-mhra-authorization-of-nulibry-fosdenopterin-for-treatment-of-mocd-type-a-in-great-britain/
NULIBRY is the first and only treatment in Great Britain for patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years The Medicines and Healthcare products Regulatory Agency’s (MHRA) decision is based on efficacy and safety data collected to date. MoCD Type A is known to impact fewer than 150 patients globally with a median survival age of four years. NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy that was approved by the U.S. Food and Drug Administration (FDA) in 2021 to reduce the risk of mortality in patients with MoCD Type A. Following this decision by the MHRA, NULIBRY is the first and only approved therapy in GB for MoCD Type A. https://sentynl.com/news/sentynl-therapeutics-receives-mhra-authorization-of-nulibry-fosdenopterin-for-treatment-of-mocd-type-a-in-great-britain/
